The law bans clawbacks, mail-order rebates, spread pricing, patient steering and networks solely composed of affiliate pharmacies, according to a news release. It also aims to block data-sharing without patients’ consent.
On the “Big Pharma” side, the legislation requires drugmakers to report price increases surpassing 15 percent after one year and cumulative list price increasing 30 percent or more within three years.
At the federal level, about half a dozen bills looking to regulate the PBM industry are wading through committees.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.